Tag: dermatology

Clinical Research: Phase 1 - Phase 4

3 Strategies for Treating Psoriasis

We’ve previously discussed several issues around psoriasis, including the pathogenesis of the condition and the challenges (and solutions!) of conducting psoriasis clinical trials. Today we turn toward three strategies for treating it. Although moisturizer may be an effective solution for some cases of mild psoriasis, many patients require medical intervention to ease their symptoms and...

Consulting

7 New and Emerging Acne Treatments

Acne is a common, complex skin disorder most people experience at some point in their lives. While many treatments are currently available, options for severe acne are limited. Additionally, clinicians are aiming to reduce long-term broad-spectrum antibiotic use, which is becoming less effective as antibiotic resistance becomes more common. Possible solutions? More effective topical treatments and targeted therapies. Here...

Consulting

6 Existing Therapeutic Strategies for Acne Management

Acne is a common chronic inflammatory skin condition with a complex pathophysiology involving multiple factors. Effective types of treatment involve both prescription and over-the-counter remedies that may be topical or systemic. While many popular therapies have been available for decades, today’s patients and physicians have more options for acne management. Additionally, new research and novel...

Clinical Research: Phase 1 - Phase 4

The Pathogenesis of Acne and What It Means for Drug Developers

Acne — specifically acne vulgaris — is the most common skin disorder in the United States, affecting up to 50 million Americans each year. While many cases are restricted to mild manifestations during one’s teenage years, acne is a highly visible condition that can have a major impact on a patient’s quality of life. It’s a disorder with the potential...

Clinical Research: Phase 1 - Phase 4

Conventional Treatments for Atopic Dermatitis

While there is currently no cure for atopic dermatitis (AD) — commonly called eczema — this prevalent condition can often be well managed through conventional drug therapies. Current AD strategies used by dermatologists include symptom relief, patient/parent education, and the prevention of secondary complications. The “Gold Standard” for Mild to Moderate Atopic Dermatitis The most frequently used therapies...

Clinical Research: Phase 1 - Phase 4

Biologics in Psoriasis Treatment

Biologics have revolutionized psoriasis treatment over the last two decades. These targeted immunomodulatory therapies act directly on the cytokine pathways that are upregulated in psoriasis and other autoimmune diseases. Two major classes make up biologics in psoriasis treatment: tumor necrosis factor (TNF) inhibitors and interleukin (IL) inhibitors. TNF Inhibitors TNF inhibitors became the first available biologic...

Consulting

What Is Atopic Dermatitis?

Atopic dermatitis (AD), also known as atopic eczema, is a common skin disorder affecting millions of people worldwide. While many cases are mild, AD can take a significant financial and emotional toll on patients and their loved ones. What are the symptoms of atopic dermatitis? AD is characterized by skin barrier function abnormalities and skin...

Consulting

The Complicated Pathogenesis of Psoriasis

Psoriasis is an autoimmune disease that affects 7.5 million people in the United States and roughly 100 million worldwide. While its main manifestation is in unsightly, often irritating skin lesions, many patients also experience painful psoriatic arthritis. Additionally, psoriasis often comes with a wide range of other chronic conditions, including Type 2 diabetes, cardiovascular disease and...

Clinical Research: Phase 1 - Phase 4

Challenges and Solutions in Conducting Psoriasis Clinical Trials

Designing and conducting psoriasis clinical trials is tricky. After all, psoriasis is a highly variable group of conditions that produce a range of debilitating and often subjective symptoms. So how do researchers assess efficacy in novel psoriasis treatments? Read on for the answer. Considerations for Psoriasis Trials In clinical practice, broad global assessments are used...

Consulting

More Than Skin Deep: Beyond the Dermatological Manifestations of Psoriasis

Psoriasis is caused by dysregulated interactions of the innate and adaptive immune system in skin epithelium and connective tissue, including the activation and proliferation of T helper cells. As an autoimmune disorder causing widespread inflammation, it is unsurprising that psoriasis is associated with a number of non-dermatological conditions. Continued psoriasis research may give insight into the etiology...